News
CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...
CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...
At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...
The absolute and relative HIV-attributable cancer burden varies globally. These data can inform region-specific planning and evaluation of HIV control, as well as cancer-specific interventions such as ...
Michael R. Jackson's hit Broadway musical, A Strange Loop, was in part inspired by the crass way HIV was treated by Tyler ...
3d
Barchart on MSNThis Overlooked Biotech Stock Is a Buy for Its Hidden Strengths
Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...
4d
Investor's Business Daily on MSNGilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...
The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.
The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results